Evaluating poor performance status and braf mutation as predictive factor for grade 3-5 immune-related adverse events in patient with advanced non-small-cell lung cancer.
Phase of Trial: Phase IV
Latest Information Update: 10 Nov 2017
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Nov 2017 New trial record
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer.